精优药业(00858)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00858 精优药业

未开盘 08-21 16:08:06

0.080

+0.001

+1.27%

最高0.080	最低0.078	成交量83.00万
今开0.078	昨收0.079	日振幅2.53%
总市值2.32亿	流通市值2.32亿	总股本29.00亿
成交额6.50万	换手率0.03%	流通股本29.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00858","market":"HK","secType":"STK","nameCN":"精优药业","latestPrice":0.08,"timestamp":1787299686872,"preClose":0.079,"halted":0,"volume":830000,"delay":0,"changeRate":0.012658227848101278,"floatShares":2900000000,"shares":2900000000,"eps":-0.3952,"marketStatus":"未开盘","change":0.001,"latestTime":"08-21 16:08:06","open":0.078,"high":0.08,"low":0.078,"amount":65020,"amplitude":0.025316,"askPrice":0.08,"askSize":1110000,"bidPrice":0.078,"bidSize":180000,"shortable":0,"etf":0,"ttmEps":-0.338,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"listingDate":920995200000,"exchange":"SEHK","adjPreClose":0.079,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.5971223021754568,"lotSize":10000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00858","defaultTab":"news","newsList":[{"id":"1115837154","title":"精优药业：Starcoin Foundation减持，好仓比例降至0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115837154","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115837154?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:12","pubTimestamp":1786698776,"startTime":"0","endTime":"0","summary":"Starcoin Foundation于2026年8月11日减持所持全部精优药业股份，持股量降至0%。Starcoin Foundation此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为0股，好仓比例降至0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199664560","title":"精优药业：仰融减持，好仓比例降至0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199664560","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199664560?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:12","pubTimestamp":1786698735,"startTime":"0","endTime":"0","summary":"仰融于2026年8月11日完成出售精优药业股份，持股量降至5%以下。仰融此次减持前持有精优药业好仓9.00亿股，占比31.03%；减持后持股量为0，好仓比例降至0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121642924","title":"精优药业2026年7月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1121642924","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121642924?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:57","pubTimestamp":1785747473,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司于2026年8月3日发布了截至2026年7月31日的证券变动月报。公告显示，公司当月未发生新增股份发行、购回或注销事项，整体股本结构与上月相比保持不变。根据公告，公司截至7月底的法定股本为200,000,000港元，分为20,000,000,000股普通股，每股面值0.01港元；上月及本月底法定股本额度一致，未发生增减变动。公告由执行董事及公司秘书王秀娟签署，精优药业再次强调将持续遵守香港联交所《上市规则》及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117742241","title":"精优药业（00858）公布将自2026年8月3日起更改百慕达注册办事处及股份过户登记总处地址","url":"https://stock-news.laohu8.com/highlight/detail?id=1117742241","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117742241?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:35","pubTimestamp":1785486928,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司（00858）7月31日公告称，公司董事会决定自2026年8月3日起，更改其在百慕达的注册办事处及股份过户登记总处地址，新的地址为：Richmond House, 12 Par-la-Ville Road, Hamilton HM 08, Bermuda。\n公告同时确认，公司于香港的股份过户登记分处仍为卓佳证券登记有限公司，相关股份过户登记事宜应继续递交至香港夏悫道16号远东金融中心17楼的卓佳证券登记有限公司。\n截至公告日，公司执行董事包括谢毅博士、郭懿博士、程勇先生、楼屹博士及王秀娟女士，独立非执行董事为金松女士、曾立博士及杨晓蓉女士。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103564275","title":"精优药业2026财年由盈转亏，全年录得9.797亿港元亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=1103564275","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103564275?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:45","pubTimestamp":1785401153,"startTime":"0","endTime":"0","summary":"精优药业于百慕大注册，在香港联合交易所有限公司上市。公司主要从事医药制造与分销等业务，涵盖自有品牌药物的研发与生产，并通过可转换债券等财务投资进行协同管理。公司董事会由执行董事及独立非执行董事组成，下设审核委员会、薪酬委员会及提名委员会，分别负责审计、薪酬和提名等事宜。在截至2026年3月31日止的报告期内，公司财务业绩出现明显下滑，归属于公司所有者的亏损约为9.797亿港元，而上一财年则录得约2.23亿港元的盈利。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"精优药业2026财年由盈转亏，全年录得9.797亿港元亏损","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134927894","title":"精优药业(00858)计划于2026年8月28日召开年度股东大会 将审议发行及回购股份等多项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1134927894","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134927894?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:41","pubTimestamp":1785400911,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司7月31日发布公告称，公司已定于2026年8月28日上午11时在香港铜锣湾怡和街88号富豪香港酒店低座二楼聚贤会议厅及聚贤厅II召开股东周年大会，审议公司截至2026年3月31日止年度的多项事项。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121876598","title":"精优药业拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1121876598","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121876598?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:37","pubTimestamp":1785400636,"startTime":"0","endTime":"0","summary":"精优药业公告称，董事会已议决在股东大会上提呈一项回购股份授权方案，允许公司于香港联合交易所有限公司或其他获认可证券交易所回购最高不超过已发行股份总数10%的股份。基于公司已发行2,900,000,000股股份，此次回购上限约2.90亿股。董事会认为，适时回购股份有助于提升每股资产净值和每股盈利水平，符合公司和股东的整体最佳利益。公告显示，过去一年，精优药业于港股市场的最高成交价为每股0.149港元，最低为每股0.054港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"精优药业拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135341705","title":"阿拉伯巴勒斯坦投资公司向退出英属维尔京群岛迈进","url":"https://stock-news.laohu8.com/highlight/detail?id=1135341705","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135341705?lang=zh_cn&edition=full","pubTime":"2026-07-20 17:20","pubTimestamp":1784539230,"startTime":"0","endTime":"0","summary":"阿拉伯巴勒斯坦投资有限公司（Arab Palestinian Investment Company Ltd）在退出英属维尔京群岛（BVI）的程序方面取得重大进展。该公司现已能够推进完成相关退出流程。\n这一积极进展源于BVI主管法院作出的一项决定，该决定解除了此前在此方面施加的限制。预计此项裁决将为完成与终止该公司在BVI法律实体地位相关的剩余程序扫清障碍、铺平道路。\n公司表示，将继续密切关注这些程序，直至所有退出步骤全部完成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118923595","title":"精优药业6月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1118923595","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118923595?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:52","pubTimestamp":1783072360,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司于2026年7月3日发布截至2026年6月30日的股份变动月报表。报告显示，公司本月股本结构保持稳定，未有新增发行、回购或注销活动。在股份期权与股权激励方面，精优药业于2022年9月2日采纳的购股权计划上月底结存的股份期权数量为76,500,000份，本月无增减变动，期末仍为76,500,000份。本月内无因行使期权而增加已发行股份或转让库存股份。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647550688","title":"精优药业(00858)公布年度业绩 拥有人应占亏损约9.8亿港元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2647550688","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647550688?lang=zh_cn&edition=full","pubTime":"2026-06-30 23:19","pubTimestamp":1782832767,"startTime":"0","endTime":"0","summary":"智通财经APP讯，精优药业(00858)公布截至2026年3月31日止年度业绩，持续经营业务收益约5148.1万港元，同比减少7.12%;公司拥有人应占亏损约9.8亿港元，同比盈转亏;每股亏损39.52港仙。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"精优药业(00858)公布年度业绩 拥有人应占亏损约9.8亿港元 同比盈转亏","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00858","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193277166","title":"精优药业预计财年录得未变现亏损8-8.5亿港元，主要涉Starcoin集团可换股债券等","url":"https://stock-news.laohu8.com/highlight/detail?id=1193277166","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193277166?lang=zh_cn&edition=full","pubTime":"2026-06-23 21:19","pubTimestamp":1782220754,"startTime":"0","endTime":"0","summary":"精优药业预计，在截至2024年3月31日的财政年度，将录得约8亿至8.5亿港元的未变现亏损。此项亏损主要源于对Starcoin集团可换股债券及其他金融资产投资的公允价值变动。\n公司指出，相关公允价值评估是基于管理层在报告期末可获得的信息及假设。最终财务数据将以公司经审核的年度业绩公告为准。\n此次预计亏损为非现金项目，不会对集团当前现金流及营运构成即时影响。精优药业强调，集团主营业务维持正常。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645316858","title":"精优药业(00858)发盈警 预计年度取得至少9.5亿港元的亏损 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2645316858","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645316858?lang=zh_cn&edition=full","pubTime":"2026-06-23 21:18","pubTimestamp":1782220721,"startTime":"0","endTime":"0","summary":"智通财经APP讯，精优药业(00858)发布公告，集团预期截至2026年3月31日止年度将录得至少9.5亿港元的亏损，而对比截至2025年3月31日止年度为录得盈利。预期转盈为亏主要由于若干非现金项目，包括(i)对本集团于(由星太链集团有限公司发行而其股份于2026年5月6日起在联交所暂停买卖)可换股债券投资确认未变现亏损介乎8亿港元至8.5亿港元之间，而去年相应期间同一项目则录得公平值变动的收益;及(ii)对本集团于一间联营公司的权益以及对该联营公司应收贷款的减值拨备合计约1.4亿港元。于截至2026年3月31日止年度，本集团经营分类的表现维持稳定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"精优药业(00858)发盈警 预计年度取得至少9.5亿港元的亏损 同比盈转亏","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00858","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154708509","title":"精优药业更新2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1154708509","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154708509?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:33","pubTimestamp":1780569182,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司于2026年6月4日发布截至2026年5月31日止的股份变动月报表。报告显示，公司于5月底的注册股本与已发行股份并无变动，股本结构保持稳定。公司法定股份总数为20,000,000,000股，面值每股港币0.01元，法定股本为港币200,000,000元。公司可转债部分保持不变，2033年到期的零息可换股债券余额为港币352,715,000元，若于转股价港币0.6413元全部转换，最多可发行550,000,000股。至此，精优药业于2026年5月末并无股份发行及回购活动，整体股本维持不变。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107982849","title":"精优药业4月股份变动月报表披露 发行股本增至2,900,000,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1107982849","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107982849?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:57","pubTimestamp":1778057864,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司于2026年5月6日发布截至2026年4月30日的证券变动月报表。公告显示，公司本月底注册股本维持20,000,000,000股，面值每股0.01港元，注册股本总额为200,000,000港元，与上月无变化。已发行股份方面，公司在报告期内从上月底的2,550,000,000股增至2,900,000,000股，净增350,000,000股。公司股权激励相关的购股权计划项下的购股权数量保持不变，月末潜在可发行股份合计162,500,000股。截至本月末，公司确认其符合香港联合交易所有限公司的相关上市规则及法规要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104548058","title":"精优药业因可换股债转股发行3.5亿股股份 占比13.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104548058","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104548058?lang=zh_cn&edition=full","pubTime":"2026-04-14 16:36","pubTimestamp":1776155798,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司(00858)于2026年4月14日发布公告，披露公司根据早前发行的可换股债券转换安排，以每股0.6413港元的发行价增发3.5亿股新股份，合计金额约2.24亿港元。该批股份约占本次发行前公司已发行股本的13.73%。\n本次增发完成后，公司已发行股本由25.5亿股增加至29亿股。公司在公告中确认，相关发行事宜已获得董事会正式授权，并严格遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由执行董事及公司秘书王秀娟签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627416234","title":"精优药业(00858)因转换可转换债券而发行3.5亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627416234","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627416234?lang=zh_cn&edition=full","pubTime":"2026-04-14 16:36","pubTimestamp":1776155767,"startTime":"0","endTime":"0","summary":"智通财经APP讯，精优药业(00858)发布公告，于2026年4月14日因转换可转换债券而发行3.5亿股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BNDW","00858","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104701197","title":"精优药业2026年3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1104701197","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104701197?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:38","pubTimestamp":1775119115,"startTime":"0","endTime":"0","summary":"精优药业于2026年4月2日发布截至2026年3月31日的股份变动月报表。报告显示，公司本月未进行任何新增发行、购回或注销，股本结构保持稳定。截至本月末，已发行股份总数仍为2,550,000,000股，未持有任何库藏股。截至2026年3月31日，已授出的股份期权数目为76,500,000份，报告期内并未因此发行新股。公司表示将继续遵守香港联交所《上市规则》及相关法律规定，并定期公布股本变动信息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622582236","title":"精优药业(00858)拟出售所持星太链可换股债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2622582236","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2622582236?lang=zh_cn&edition=full","pubTime":"2026-03-27 21:18","pubTimestamp":1774617531,"startTime":"0","endTime":"0","summary":"智通财经APP讯，精优药业 公布，于2026年3月27日，订约方订立不具法律约束力的谅解备忘录，据此，公司拟向潜在买方Marvel Nice Limited出售全部可换股债券及╱或将公司于第四份修订契据项下的所有权益及利益转让予潜在买方。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175336299","title":"精优药业发行可转换债券 总本金达7.15亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175336299","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175336299?lang=zh_cn&edition=full","pubTime":"2026-03-27 21:05","pubTimestamp":1774616714,"startTime":"0","endTime":"0","summary":"精优药业（股份代号：00858）宣布发行可转换债券，债券总本金金额为7.15亿港元。此次发行的可转换债券将为公司提供新的融资渠道，有望支持其未来业务拓展及营运资金需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112064823","title":"精优药业（00858）完成长春精优10.06%股份回购 持股比例升至89.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112064823","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112064823?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:05","pubTimestamp":1773738350,"startTime":"0","endTime":"0","summary":"精优药业控股有限公司17日公告称，旗下间接持股 80.46% 的非全资附属公司长春精优已于 2026 年 3 月 16 日完成股份回购及注销程序。此次回购涉及长春精优 10.06% 已发行股本，并同步注销，对应注册资本由 4,543 万元人民币降至 4,086 万元人民币，股份总数由 4,543 万股减至 4,086 万股。完成回购后，精优药业通过精优企业对长春精优的持股比例由 80.46% 提升至 89.46%；其余股权由股东 A、股东 B、股东 C 分别持有 4.48%、3.82% 及 2.24%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00858"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.extrawell.com.hk","stockEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":-0.0244},{"period":"3month","weight":-0.0123},{"period":"6month","weight":-0.0476},{"period":"1year","weight":-0.36},{"period":"ytd","weight":-0.0244}],"compareEarnings":[{"period":"1week","weight":0.0355},{"period":"1month","weight":0.0449},{"period":"3month","weight":0.0158},{"period":"6month","weight":-0.0153},{"period":"1year","weight":0.036},{"period":"ytd","weight":0.0148}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"精优药业控股有限公司是一家主要从事开发、制造及销售药品的投资控股公司。该公司主要通过三个分部运营业务。制造分部从事医药产品的开发、制造及销售业务。其自制产品包括转移因子口服溶液、贯新克及洲邦等。贸易分部从事进口药品的推广及经销业务。其进口产品包括美利巴及适今可。基因开发分部从事基因相关技术的商业开发及研发业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.407407,"avgChangeRate":0.054952},{"month":2,"riseRate":0.518519,"avgChangeRate":0.035392},{"month":3,"riseRate":0.296296,"avgChangeRate":0.026028},{"month":4,"riseRate":0.321429,"avgChangeRate":0.010323},{"month":5,"riseRate":0.392857,"avgChangeRate":0.096347},{"month":6,"riseRate":0.392857,"avgChangeRate":0.057621},{"month":7,"riseRate":0.25,"avgChangeRate":-0.039625},{"month":8,"riseRate":0.357143,"avgChangeRate":-0.034875},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.023131},{"month":10,"riseRate":0.333333,"avgChangeRate":0.010027},{"month":11,"riseRate":0.423077,"avgChangeRate":0.02567},{"month":12,"riseRate":0.296296,"avgChangeRate":-0.022304}],"exchange":"SEHK","name":"精优药业","nameEN":"EXTRAWELL PHAR"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"精优药业(00858)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供精优药业(00858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"精优药业,00858,精优药业股票,精优药业股票老虎,精优药业股票老虎国际,精优药业行情,精优药业股票行情,精优药业股价,精优药业股市,精优药业股票价格,精优药业股票交易,精优药业股票购买,精优药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"精优药业(00858)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供精优药业(00858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}